Last updated:
July 30, 2015
Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
-
Switching to dual
therapy (atazanavir/ritonavir+lamivudine) vs. standard triple therapy
(atazanavir/ritonavir+2 nucleos[t]ides) is safe and effective
in virologically
suppressed patients: 48-week results of a randomized clinical trial (SALT
study)
J.A. Perez-Molina, R. Rubio, A. Rivero, et al
Abstract
-
Open label,
randomized, crossover, single-dose, bioavailability evaluation of
atazanavir/ritonavir FDC Tablets 300 mg/100 mg with that of REYATAZ 300 mg
and
Norvir 100 mg
under fed and fasting conditions
I. Bhushan, A. Deshmukh, S. Chakraborty, et al
Abstract
-
Atazanavir and
ritonavir pharmacokinetics with telaprevir-based HCV treatment (ANRSHC26)
A. Barrail-Tran, J. Braun, C. Vincent, et al
Abstract
-
Equivalence of
boosted atazanavir based regimens and currently effective HAART regimens
with other PI's/NNRTI's in HIV+ children and adolescents with elevated lipid
levels
J. Piatt, J. Foti, K. Bickes, et al
Abstract
-
Voluntary license
and technology transfer for local production of atazanavir in Brazil: a way
forward or a step back to the sustainability of Brazil´s universal access to
ARVs policy?
P. Villardi, M. Vieira, F. Fonseca
Abstract
-
48-week changes in
bone mineral density in HIV-1 infected subjects treated with
atazanavir/ritonavir monotherapy vs ATV/r+2N(t)RTIs: a sub-study of the
MODAt trial
V. Spagnuolo, M. Borderi, L. Galli, et al
Abstract
-
Comparison of
effects of atazanavir, raltegravir, or darunavir with FTC/tenofovir on
biomarkers of systemic inflammation, macrophage and T cell activation: ACTG
A5260s
T. Kelesidis, T.T.T. Tran, G.A. McComsey, et al
Abstract
-
Comparing the
incidence and identifying risk factors for nephrolithiasis among patients
exposed to atazanavir, other PIs and PI-free regimens
E. Nkhoma, M. Kumar, P. Hines, et al
Abstract
XIX International AIDS Conference
|
-
Atazanavir
pharmacokinetics and efficacy and safety outcomes by sex in AIDS Clinical Trials
Group Study 5202 (A5202)
C. Venuto, K. Mollan, Q. Ma, et al
Abstract
-
The incidence of the
hypertriglyceridemic waist phenotype in a randomized prospective comparison
between atazanavir/ritonavir (ATV/r) and lopinavir/ritonavir (LPV/r) each in
combination with tenofovir DF/emtricitabine (TDF/FTC) in antiretroviral naive
HIV
G. Moyle, W. Hu2, R. Wang2 V. Wirtz, et al
Abstract
-
Complicated
atazanavir-associated cholelithiasis: a report of eight documented cases among
11 cases
Y. Poinsignon, F. Borsa-Lebas,
H. Jantzem, et al
Abstract -
Economic and
quality adjusted life year (QALY) comparison of lopinavir/ritonavir (LPV/r) and
atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral (ARV)
naïve Colombian HIV patients in 2011
K. Simpson, R. Baran, S. Kirbach, et al
Abstract
-
A WEEK-IN-REVIEW FEATURED
REPORT
Comparative
effectiveness of continuing a virologically effective first-line boosted
protease inhibitor combination or of switching to a three-drug regimen
containing boosted atazanavir
J.-M. Lacombe, S. Abgrall,,J. Ghosn, et al
Abstract
-
Analysis of efficacy
by baseline viral load: phase 3 study comparing
elvitegravir/cobicistat/emtricitabine/tenofovir
DF (quad) versus ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in
treatment-naïve HIV-1-positive subjects: week 48 res
E. DeJesu J. Rockstroh, K. Henry, et al
Abstract
-
Treatment
simplification to atazanavir/ritonavir plus lamivudine QD in patients on two
NRTIs plus atazanavir/ritonavir with optimal virologic control:
96 weeks follow-up
of a pilot study (Atazanavir and Lamivudine Simplification Study, ATLAS)
M. Fabbiani, M. Colafigli, S. Farina, et al
Abstract
|
XX
International AIDS Conference
Atazanavir
Main Page